1Byrd J,Mrozek K,Dodge R,et al.Pretreatment cytogenetic abnormalities are predictive of induction success,cumulative incidence of relapse,and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B (CALGB 8461)[J].Blood,2002,100:4325-4336.
2Lowenberg B,van Putten W,Theobald M,et al.Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia[J].N Engl J Med,2003,349:727-729.
3Bradstock K,Mathews J,Lowenthal R,et al.A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine[J].Blood,2005,105:481-488.
4Burnett AK,Wheatley AH,Goldstone RF,et al.The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse:results of the UK MRC AML10 Trial[J].Br J Haematol,2002,118:385-400.
5Fung H,Stein A,Slovak M,et al.A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia:impact of cytogenetic character istics on transplantation outcome[J].Biol Blood Marrow Transplant,2003,9:766-771.
6Wadleigh M,Richardson PG,Zahrieh D,et al.Prior gemtuzumab ozogamicin exposure significantly in creases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation[J].Blood,2003,102:1578-1582.
7Kantarjian H,Gandhi V,Cortes J,et al.Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia[J].Blood,2003,102:2379-2386.
8Roboz G,Jolivet J,Kelner M,et al.Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukemia (AML)[abstract][J].Proc Am Soc Clin Oncol,2005,23:584s.
9Ohno R,Asou N.The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia[J].Ann Hematol,2004,83 (Suppl 1):S77-S78.
10Okbuget N,Hoelzer D,Arnold R,et al.Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL)[J].Hemat/Oncol Clin North Am,2000,14:1307-1325.
3Faded S, Gandhi V, Obrien s, et al. Result of a phase 1 - 2 study of clofarabine in combination with Ara. C in relapsed and refractory acute leukemia [ J ]. Blood, 105 (2) :940 - 947.
4LARSON R A, SIEVERS E L ' STADTMAUER E A, et al. Final re- port of the eficacy and safety of gemtuzumab ozogamieln (Mylotarg)in patients with CD33 - positive acute myeloid leukemia in firs [ recur- renee [ J ]. Cancer,2005,104 (7) : 1442 - 1452.
5Marcucci G, Moser B, BlumW ,'et al. A Phase Ⅲ randomized trial of intensive induction and consolidation chemotherapy oblimerson, a pro-apoptotic Bcl -2 antisense oligonueleotide in afttreated acute myeloid leukemia patients > 60 years old [J]. J ClinOncol, 2007,25 ( 18 Suppl ) :7012.
6MARCUCCI G,BYRD J C ,DAI G,et al. Phase 1 and pharmacodyna- mic studies of G3139 ,a Bc1-2 antiscnse oligonucleotide,in combina- tion with chemotherapy in refractory or relapsed acute leukemia [ J]. Blood,2003,101 (2) :425 -432.
7Bradstock K, Mathews JP, Lowenthal RM, et al. A randomized trial of highversus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood, 2005, 105(2) : 481-488.
8Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 TriM. Br J Haematol, 2002, 118(2) : 385-400.
10Fung HC, Stein A, Slovak M, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia:impact of cytogenetie characteristics on transplantation outcome. Biol Blood Marrow Transplant, 20(13, 9( 12): 766-771.
